Fig. 3: Validation of the lncRNA TP53TG1/miR-96-5p/STK17B ceRNA network mechanism. | npj Precision Oncology

Fig. 3: Validation of the lncRNA TP53TG1/miR-96-5p/STK17B ceRNA network mechanism.

From: Methionine deprivation inhibits glioma proliferation and EMT via the TP53TG1/miR-96-5p/STK17B ceRNA pathway

Fig. 3

A, B TP53TG1 is either overexpressed or knocked down in glioma cells, and protein level of STK17B is examined. C, D The expression level of miR-96-5p determined following TP53TG1 overexpression or knockdown. E, F Protein level of STK17B is assessed after adding miR-96-5p inhibitor or mimics. G The protein level of STK17B is assessed using western blot. H Binding sites are predicted, and wild-type and mutant luciferase vectors constructed. Error bars represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Back to article page